[go: up one dir, main page]

WO2014172448A3 - Anticorps diriges contre le recepteur d'activine de type ii (actrii) - Google Patents

Anticorps diriges contre le recepteur d'activine de type ii (actrii) Download PDF

Info

Publication number
WO2014172448A3
WO2014172448A3 PCT/US2014/034344 US2014034344W WO2014172448A3 WO 2014172448 A3 WO2014172448 A3 WO 2014172448A3 US 2014034344 W US2014034344 W US 2014034344W WO 2014172448 A3 WO2014172448 A3 WO 2014172448A3
Authority
WO
WIPO (PCT)
Prior art keywords
actrii
receptor type
activin receptor
chain polypeptide
directed against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/034344
Other languages
English (en)
Other versions
WO2014172448A2 (fr
Inventor
Petra Verdino
Peter Bowers
David King
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anaptysbio Inc
Original Assignee
Anaptysbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anaptysbio Inc filed Critical Anaptysbio Inc
Publication of WO2014172448A2 publication Critical patent/WO2014172448A2/fr
Publication of WO2014172448A3 publication Critical patent/WO2014172448A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un polypeptide à chaîne lourde d'immunoglobuline isolé et un polypeptide à chaîne légère d'immunoglobuline isolé qui se lient à une protéine récepteur d'activine de type II (ActRII) (par exemple, l'un ou l'autre et les deux de ActRIIA et/ou ActRIIB). L'invention concerne un agent de liaison à ActRII qui comprend le polypeptide à chaîne lourde d'immunoglobuline et le polypeptide à chaîne légère d'immunoglobuline mentionnés ci-dessus. L'invention concerne également des vecteurs, des compositions et des procédés d'utilisation associés de l'agent de liaison à ActRII pour traiter une maladie à médiation par ActRII.
PCT/US2014/034344 2013-04-17 2014-04-16 Anticorps diriges contre le recepteur d'activine de type ii (actrii) Ceased WO2014172448A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361812789P 2013-04-17 2013-04-17
US61/812,789 2013-04-17

Publications (2)

Publication Number Publication Date
WO2014172448A2 WO2014172448A2 (fr) 2014-10-23
WO2014172448A3 true WO2014172448A3 (fr) 2015-01-08

Family

ID=51731973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/034344 Ceased WO2014172448A2 (fr) 2013-04-17 2014-04-16 Anticorps diriges contre le recepteur d'activine de type ii (actrii)

Country Status (1)

Country Link
WO (1) WO2014172448A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
WO2017062835A2 (fr) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
US20170240639A1 (en) * 2016-02-22 2017-08-24 Acceleron Pharma Inc. Actrii antagonists for use in increasing immune activity
PL3426680T3 (pl) * 2016-03-10 2025-03-31 Acceleron Pharma Inc. Białka wiążące receptor aktywiny typu 2 i ich zastosowania
JP7669291B2 (ja) * 2019-05-30 2025-04-28 アクセレロン ファーマ インコーポレーテッド Ａｃｔｒｉｉ結合性タンパク質及びその使用
WO2025027052A1 (fr) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Conjugués d'anticorps et protéines de fusion

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087000A1 (en) * 2005-08-19 2007-04-19 Walsh Frank S Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
US20100272734A1 (en) * 2009-04-27 2010-10-28 Novartis Ag Compositions and methods for increasing muscle growth
US20110052582A1 (en) * 2009-08-28 2011-03-03 Roche Glycart Ag Humanized Anti-CDCP1 Antibodies
US20110064751A1 (en) * 2009-08-17 2011-03-17 Roche Glycart Ag Targeted immunoconjugates

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087000A1 (en) * 2005-08-19 2007-04-19 Walsh Frank S Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
US20100272734A1 (en) * 2009-04-27 2010-10-28 Novartis Ag Compositions and methods for increasing muscle growth
US20110064751A1 (en) * 2009-08-17 2011-03-17 Roche Glycart Ag Targeted immunoconjugates
US20110052582A1 (en) * 2009-08-28 2011-03-03 Roche Glycart Ag Humanized Anti-CDCP1 Antibodies

Also Published As

Publication number Publication date
WO2014172448A2 (fr) 2014-10-23

Similar Documents

Publication Publication Date Title
WO2014172448A3 (fr) Anticorps diriges contre le recepteur d'activine de type ii (actrii)
WO2014179664A3 (fr) Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
ZA201706740B (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2015106080A3 (fr) Anticorps dirigés contre l'interleukine-33 (il-33)
WO2016126858A3 (fr) Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
HK1211223A1 (en) Human monoclonal anti-pd-l1 antibodies and methods of use
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
ZA201708265B (en) Tigit-binding agents and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA201990208A1 (ru) Химерные антигенные рецепторы, нацеленные на bcma, и способы их применения
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
WO2018017864A3 (fr) Agents de liaison à pvrig et leurs utilisations
HK1259075A1 (zh) Bcma抗体和其用以治疗癌症和免疫病症的用途
WO2014165082A3 (fr) Anticorps et procédés de détection
EP4491195A3 (fr) Anticorps bispécifiques tétravalents et procédés de making et d'utilisation de ceux-ci
EA201892440A1 (ru) Антитела к tl1a и их применения
EP3954703A3 (fr) Molécules de liaison trispécifiques et leurs procédés d'utilisation
EP4406554A3 (fr) Formulations d'anticorps anti-cd3
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
EP4253959A3 (fr) Anticorps anti-idiotypiques dirigés contre la partie de liaison à l'antigène d'une molécule de liaison à bcma
WO2015009740A3 (fr) Agents de liaison anti-mucine 1 et leurs utilisations
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
HK1220207A1 (zh) 人源化抗n2抗体
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
WO2015116569A3 (fr) Anticorps dirigés contre la famille des récepteurs à domaine discoïdine, élément 1 (ddr1)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14785005

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14785005

Country of ref document: EP

Kind code of ref document: A2